{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:38:27Z","timestamp":1784061507378,"version":"3.55.0"},"reference-count":49,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation that may lead to kidney failure. Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of aHUS. This study assessed the real\u2010world effectiveness and safety of switching to ravulizumab from eculizumab in kidney transplant recipients with aHUS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Global aHUS Registry is a multicenter study enrolling patients with aHUS since 2012. Effectiveness and safety outcomes were assessed in kidney transplant recipients with aHUS who switched to ravulizumab from eculizumab up to September 2, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 38 patients received a kidney transplant before ravulizumab initiation; 27 patients with \u22653 months of ravulizumab treatment were included in the patient characteristics and effectiveness analyses. Median (range) time on eculizumab and ravulizumab treatment was 66.1\u00a0(3.7,\u00a0158.3) and 24.1 (4.2, 49.3) months, respectively (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a027); time from last kidney transplantation to ravulizumab initiation was 65.9 (3.7, 184.0) months. Following ravulizumab initiation, laboratory parameters remained stable, and no kidney transplant rejections\/graft failures were reported. In the safety analysis (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a038), 23 adverse events were reported in 19 patients (50.0%) at or after ravulizumab initiation, and none were considered treatment\u2010related. No new events of thrombotic microangiopathy or kidney impairment and no meningococcal infections or deaths were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis from the Global aHUS Registry provides real\u2010world evidence to demonstrate that the transition to ravulizumab from eculizumab in kidney transplant recipients with aHUS is successful, with stable graft function with no treatment\u2010related safety concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier: NCT01522183<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ctr.70278","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:30:03Z","timestamp":1756395003000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis"],"prefix":"10.1111","volume":"39","author":[{"given":"Anja","family":"Gaeckler","sequence":"first","affiliation":[{"name":"Department of Nephrology University Hospital Essen University Duisburg\u2010Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Al\u2010Dakkak","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Saval","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Herman","family":"Dieperink","sequence":"additional","affiliation":[{"name":"Department of Nephrology Odense University Hospital  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margriet","family":"Eygenraam","sequence":"additional","affiliation":[{"name":"aHUS Canada  Brampton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Greenbaum","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology Emory University School of Medicine and Children's Healthcare of Atlanta  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Isbel","sequence":"additional","affiliation":[{"name":"Department of Kidney and Transplant Services The University of Queensland and Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Vande","family":"Walle","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Medical Genetics Ghent University Hospital  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744\u20109987.12763"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620\u2010016\u20100357\u20107"},{"key":"e_1_2_10_5_1","unstructured":"SOLIRIS Prescribing Information(US Food and Drug Administration 2024) accessed Jan 30 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761333s000lbl.pdf."},{"key":"e_1_2_10_6_1","unstructured":"Soliris Summary of Product Characteristics(European Medicines Agency 2024) accessed Jan 30 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/soliris\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_7_1","unstructured":"Ravulizumab Prescribing Information(US Food and Drug Administration 2024) accessed Feb 11 2025 https:\/\/alexion.us\/\u2010\/media\/alexion_global\/documents\/regulatory\/north\u2010america\/usa\/2024\/english\/ultomiris_uspi.pdf."},{"key":"e_1_2_10_8_1","unstructured":"ULTOMIRIS Japanese Prescribing Information 2023 accessed Jan 30 2025 https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/870056_6399427A1027_1_10."},{"key":"e_1_2_10_9_1","volume-title":"Summary of Product Characteristics","author":"Ultomiris","year":"2024"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.046"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.03.884"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467\u2010020\u201004774\u20102"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100855"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04760512"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02210310"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.02.029"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.155"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.811504"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070919"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12077"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100897"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2015.07.005"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20106143.2012.04252.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.05.015"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620\u2010016\u20100357\u20107"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.214"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.06.020"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882\u2010024\u201003638\u20103"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882\u2010015\u20100195\u20101"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620\u2010024\u201002005\u20107"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10846"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27461"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1264310"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0036"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100683"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.16552"},{"key":"e_1_2_10_39_1","unstructured":"National Institute for Health and Care Excellence: Ravulizumab for Treating Atypical Haemolytic Uraemic Syndrome 2021 https:\/\/www.nice.org.uk\/guidance\/ta710."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2027706"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019040331"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2021.09.063"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620\u2010021\u201001045\u20107"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882\u2010020\u201001847\u20100"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/20543581211003763"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa096"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258319"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad063c_5816"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001289"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jambio\/lxae292"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.70278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ctr.70278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.70278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:28:11Z","timestamp":1773008891000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.70278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/ctr.70278"],"URL":"https:\/\/doi.org\/10.1111\/ctr.70278","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"2025-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70278"}}